Numinus is at the forefront of transformative changes in treating mental illness, addictions and trauma while addressing the universal desire to heal and be well.Through Numinus Bioscience (formerly Salvation Bioscience), Numinus has a dealer's licence which allows the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline, as well as produce and extract psilocybin from mushrooms. Numinus is seeking to expand the licence to include activities such as import/export, testing and R&D. The expanded licence will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through the supply and distribution of these substances. Through Numinus Wellness, the company is dedicated to providing access to therapies that enhance and supplement existing options. A purpose-built facility is planned for Vancouver in 2021.